rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Shelia M. Violette

Chief Scientific Officer

Company insider

Files Form 4 as: Chief Scientific Officer, Q32 Bio.

In numbers

Trades disclosed
27
Buys
0
Sells
4
Bought
$0
Sold
$131K
Companies
1
Companies where not an officer
0
First trade
25 Mar 2024
Last trade
6 Oct 2026
Last filed
14 Oct 2026

Companies traded

Where they are an officer
QTTB Q32 BioOfficer · Biotechnology · last 6 Oct 20260 buys · 4 sells

Activity over time

1 Aug 2025 – 1 Oct 2026
10Aug 25Dec 25Mar 26Jul 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
6 Oct 2026filed 14 Oct 2026QTTB Q32 BioBiotechnologySEC FORM 4 Sold$7,629917 at $8.32filing
25 Aug 2026filed 27 Aug 2026QTTB Q32 BioBiotechnologySEC FORM 4 Sold$46K2,798 at $16.56filing
25 Aug 2026filed 27 Aug 2026QTTB Q32 BioBiotechnologySEC FORM 4 Sold$46K2,798 at $16.56filing
16 Jul 2026filed 20 Jul 2026QTTB Q32 BioBiotechnologySEC FORM 4 Code A—37,500 at $0.00filing
16 Jul 2026filed 20 Jul 2026QTTB Q32 BioBiotechnologySEC FORM 4 Code A—37,500 at $0.00filing
25 Feb 2026filed 27 Feb 2026QTTB Q32 BioBiotechnologySEC FORM 4 Sold$13K2,815 at $4.51filing
25 Feb 2026filed 27 Feb 2026QTTB Q32 BioBiotechnologySEC FORM 4 Sold$13K2,815 at $4.51filing
24 Feb 2026filed 20 Mar 2026QTTB Q32 BioBiotechnologySEC FORM 4 Code A—37,500 at $0.00filing
24 Feb 2026filed 20 Mar 2026QTTB Q32 BioBiotechnologySEC FORM 4 Code A—37,500 at $0.00filing
26 Aug 2025filed 28 Aug 2025QTTB Q32 BioBiotechnologySEC FORM 4 Sold$5,3822,990 at $1.80filing
24 Feb 2025filed 26 Feb 2025QTTB Q32 Biooption or derivative · BiotechnologySEC FORM 4 Code D—32,891 at $0.00filing
24 Feb 2025filed 26 Feb 2025QTTB Q32 Biooption or derivative · BiotechnologySEC FORM 4 Code A—32,891 at $0.00filing
24 Feb 2025filed 26 Feb 2025QTTB Q32 Biooption or derivative · BiotechnologySEC FORM 4 Code D—13,305 at $0.00filing
24 Feb 2025filed 26 Feb 2025QTTB Q32 Biooption or derivative · BiotechnologySEC FORM 4 Code A—13,305 at $0.00filing
24 Feb 2025filed 26 Feb 2025QTTB Q32 Biooption or derivative · BiotechnologySEC FORM 4 Code D—17,506 at $0.00filing
24 Feb 2025filed 26 Feb 2025QTTB Q32 Biooption or derivative · BiotechnologySEC FORM 4 Code A—17,506 at $0.00filing
24 Feb 2025filed 26 Feb 2025QTTB Q32 Biooption or derivative · BiotechnologySEC FORM 4 Code D—56,413 at $0.00filing
24 Feb 2025filed 26 Feb 2025QTTB Q32 Biooption or derivative · BiotechnologySEC FORM 4 Code A—56,413 at $0.00filing
24 Feb 2025filed 26 Feb 2025QTTB Q32 BioBiotechnologySEC FORM 4 Code A—37,500 at $0.00filing
15 Oct 2024filed 16 Oct 2024QTTB Q32 Biooption or derivative · BiotechnologySEC FORM 4 Code M—6,000 at $0.00filing

News

Q32 Bio Inc. (NASDAQ:QTTB) Stock Rated "Moderate Buy" by Wall Street AnalystsQTTB · dailypolitical.com · 25 Oct 2026Head to Head Review: Q32 Bio (NASDAQ:QTTB) vs. Applied Therapeutics (NASDAQ:APLT)QTTB · tickerreport.com · 15 Oct 2026

0 headlines in the last 90 days name Shelia M. Violette; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.

Sectors

Health Care4

Buys in green, sells in red, by the company’s sector.

Related people

Lee KalowskiCFO and President · CFO and President at Q32 Bio, filing Form 4 there in the last year
Jodie Pope MorrisonCEO · CEO at Q32 Bio, filing Form 4 there in the last year
Mary ThistleDirector · Director at Q32 Bio, filing Form 4 there in the last year
Mark T. IwickiDirector · Director at Q32 Bio, filing Form 4 there in the last year
Arthur TzianabosDirector · Director at Q32 Bio, filing Form 4 there in the last year